The Retatrutide-Cagrilintide Stack Hype Is Ahead of the Data

Retatrutide and cagrilintide, discussed together as a stack, come up constantly in weight management circles as the next Ozempic-beating combination. As of 2026, no published trial has actually tested this specific pairing. Both compounds have real, individually strong trial data. That distinction, real data for each compound separately versus tested together, matters more than it tends to get credit for in online discussion. The closest available analog is the REDEFINE 1 trial, which paired cagrilintide with semaglutide, not retatrutide, and reported 22.7 percent mean weight loss at 68 weeks, compared with 16.1 percent for semaglutide alone. Cagrilintide itself is currently approved only in the combination product CagriSema, paired with semaglutide, which Novo Nordisk has filed for regulatory review. It is not approved paired with retatrutide. The claims circulating about a Reta-Cagri stack are essentially combining two individually promising results and assuming they add together, which is a reasonable hypothesis, not a demonstrated outcome. Mechanistically, the idea is plausible: the two compounds work through different, non-overlapping receptor pathways, which is likely why the idea gained traction. Plausible is not the same as tested. If a trial combining the two is ever published, it will be a significant update worth watching, particularly for anyone considering trying to replicate the stack based on today's speculation.